Physician profile
Leonardo R Hormaza
NPI 1124039813
$75,128.33
in general payments reported to CMS, 2019-2025
15 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2021: $420 · 2022: $420 · 2023: $17K · 2024: $28K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Consulting Fee: $26K · Travel and Lodging: $12K · Food and Beverage: $4,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,680.00 |
| Consulting Fee | $25,960.00 |
| Travel and Lodging | $11,763.75 |
| Food and Beverage | $4,660.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $37,942.83 | 2023-2025 | Bylvay |
| Mirum Pharmaceuticals, INC. | $34,532.32 | 2022-2025 | Livmarli |
| Genzyme Corporation | $842.83 | 2022-2025 | |
| Abbvie INC. | $308.29 | 2019-2021 | |
| Albireo Pharma, INC. | $252.01 | 2023-2024 | Bylvay |
| Alexion Pharmaceuticals, INC. | $242.33 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $219.57 | 2022-2025 | Vpriv |
| E.R. Squibb & Sons, L.L.C. | $127.14 | 2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $125.00 | 2021 | |
| Horizon Therapeutics Plc | $124.95 | 2023 | Actimmune |
| Janssen Pharmaceuticals, INC | $111.72 | 2019-2023 | Stelara |
| Merck Sharp & Dohme LLC | $108.04 | 2019-2023 | Gardasil 9 |
| Janssen Biotech, INC. | $99.00 | 2021 | |
| Genentech, INC. | $76.84 | 2024 | Xolair |
| Pbg Puerto Rico LLC | $15.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonardo Hormaza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.